| Preview | Issue Date | Title | Author(s) |
| 2011 | Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer | Haller, D.; Tabernero, J.; Maroun, J.; de Braud, F.; Price, T.; Van Cutsem, E.; Hill, M.; Gilberg, F.; Rittweger, K.; Schmoll, H. |
| 2015 | Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant Therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial | Schmoll, H.; Tabernero, J.; Maroun, J.; de Braud, F.; Price, T.; Van Cutsem, E.; Hill, M.; Hoersch, S.; Rittweger, K.; Haller, D. |
| 2022 | Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials | McCleary, N.J.; Harmsen, W.S.; Haakenstad, E.; Cleary, J.M.; Meyerhardt, J.A.; Zalcberg, J.; Adams, R.; Grothey, A.; Sobrero, A.F.; Van Cutsem, E.; Goldberg, R.M.; Peeters, M.; Tabernero, J.; Seymour, M.; Saltz, L.B.; Giantonio, B.J.; Arnold, D.; Rothenberg, M.L.; Koopman, M.; Schmoll, H.-J.; et al. |
| 2013 | Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors | Clarke, S.; Karapetis, C.; Gibbs, P.; Pavlakis, N.; Desai, J.; Michael, M.; Tebbutt, N.; Price, T.; Tabernero, J. |
| 2007 | Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1 864 patients | Schmoll, H.; Cartwright, T.; Tabernero, J.; Nowacki, M.; Figer, A.; Maroun, J.; Price, T.; Lim, R.; Van Custem, E.; Park, Y.; McKendrick, J.; Topham, C.; Soler-Gonzalez, G.; de Braud, F.; Hill, M.; Sirzen, F.; Haller, D. |
| 2015 | Randomized trial of TAS-102 for refractory metastatic colorectal cancer | Mayer, R.J.; Van Cutsem, E.; Falcone, A.; Yoshino, T.; Garcia-Carbonero, R.; Mizunuma, N.; Yamazaki, K.; Shimada, Y.; Tabernero, J.; Komatsu, Y.; Sobrero, A.; Boucher, E.; Peeters, M.; Tran, B.; Lenz, H.J.; Zaniboni, A.; Hochster, H.; Cleary, J.M.; Prenen, H.; Benedetti, F.; et al. |
